AUTO-2

N/A

Report date: 2024/05/10 20:00:07

Base Information

Drug NameAUTO-2

Drug Alias NameAutologous CAR-T-cell-therapyChimeric antigen receptor T-cell therapyAUTO-2SUB-96123

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-BCMATumor necrosis factor receptor superfamily member 13B inhibitors

TargetsB-cell maturation proteinTumor necrosis factor receptor superfamily member 13B

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAutolus

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAutolus Ltd

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A